Home

Blueprint Medicines Corporation - Common Stock (BPMC)

99.25
+9.75 (10.89%)
NASDAQ · Last Trade: May 2nd, 2:51 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Earnings Scheduled For May 1, 2025benzinga.com
Via Benzinga · May 1, 2025
Blueprint Medicines Earnings Previewbenzinga.com
Via Benzinga · April 30, 2025
What Analysts Are Saying About Blueprint Medicines Stockbenzinga.com
Via Benzinga · April 28, 2025
Breaking Down Blueprint Medicines: 14 Analysts Share Their Viewsbenzinga.com
Via Benzinga · April 8, 2025
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Expertsbenzinga.com
Via Benzinga · March 20, 2025
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · March 17, 2025
13 Analysts Assess Blueprint Medicines: What You Need To Knowbenzinga.com
Via Benzinga · March 3, 2025
Breaking Down Blueprint Medicines: 10 Analysts Share Their Viewsbenzinga.com
Via Benzinga · February 13, 2025
Earnings Scheduled For February 13, 2025benzinga.com
Via Benzinga · February 13, 2025
Analyst Expectations For Blueprint Medicines's Futurebenzinga.com
Via Benzinga · January 27, 2025
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?benzinga.com
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
Via Benzinga · January 19, 2025
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · January 13, 2025
What Analysts Are Saying About Blueprint Medicines Stockbenzinga.com
Via Benzinga · January 2, 2025
Is NASDAQ:BPMC a Fit for high Growth Investing Strategies?chartmill.com
Why the high growth investor may take a look at BLUEPRINT MEDICINES CORP (NASDAQ:BPMC).
Via Chartmill · December 3, 2024
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analystbenzinga.com
JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities.
Via Benzinga · November 14, 2024
Key Takeaways From Blueprint Medicines Analyst Ratingsbenzinga.com
Via Benzinga · November 14, 2024
Analyst Ratings For Blueprint Medicinesbenzinga.com
Via Benzinga · October 24, 2024
15 Analysts Have This To Say About Blueprint Medicinesbenzinga.com
Via Benzinga · July 29, 2024
9 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · August 13, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · August 8, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · July 30, 2024
Expert Ratings For Blueprint Medicinesbenzinga.com
Via Benzinga · June 28, 2024
Assessing Blueprint Medicines: Insights From 16 Financial Analystsbenzinga.com
Via Benzinga · June 7, 2024
Unveiling 18 Analyst Insights On Blueprint Medicinesbenzinga.com
Via Benzinga · May 14, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 17, 2024